MktsMarkets

Spyre Therapeutics, Inc.
NASDAQ: SYREKey statistics
SYRE News
Stories mentioning SYRE from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 0.00 | 0.00 | 0.00 | |||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Operating Expenses | ||||||||
| Research & Development | ||||||||
| Sales General & Admin | ||||||||
| Total Operating Expenses | 45,641 | 57,172 | 56,888 | 41,935 | 53,567 | 61,253 | 55,392 | 44,147 |
| Operating Income (Loss) | (45,641) | (57,172) | (56,888) | (41,935) | (53,567) | (61,253) | (55,392) | (44,147) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | (30,359) | (12,497) | 40,326 | (656.00) | 2,286 | (818.00) | (18,802) | (610.00) |
| Pretax Income | (69,005) | (62,530) | (11,183) | (36,717) | (44,788) | (56,295) | (69,010) | (38,837) |
| Tax Provision | 0.00 | 0.00 | 0.00 | 0.00 | (15.00) | 1.00 | 18.00 | 0.00 |
| Net Income (Loss) | (69,005) | (62,530) | (11,183) | (36,717) | (44,773) | (56,296) | (69,028) | (38,837) |
| Earnings Per Share (Basic) | (1.36) | (0.86) | ||||||
| Earnings Per Share (Diluted) | (0.74) | (1.36) | (0.86) | |||||
| Weighted Average Shares Outstanding (Basic) | 50,889 | 45,316 | ||||||
| Weighted Average Shares Outstanding (Diluted) | 50,889 | 45,316 | ||||||
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About SYRE
Spyre Therapeutics, Inc. (NASDAQ: SYRE) is a stock listed on the Nasdaq Stock Market under the ticker symbol SYRE. It last traded at $96.56 (Oct 30, 2026, 4:00 PM ET), down 2.4% on the day. That gives Spyre Therapeutics a market capitalisation of $9.1B.
Over the past 52 weeks SYRE has traded between $21.14 and $110.17.
For the quarter ended Mar 31, 2026 it reported a net loss of $69.0M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$69.0M |
| Dec 31, 2025 | — | -$62.5M |
| Sep 30, 2025 | — | -$11.2M |
| Jun 30, 2025 | — | -$36.7M |
From Spyre Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…